AbbVie Inc.
ABBV · NYSE
ABBV · NYSE
AbbVie sells branded prescription medicines and aesthetic products, earning revenue primarily through sales to wholesalers and other distribution channels for use by patients treated by healthcare professionals. Its portfolio spans immunology, neuroscience, oncology and aesthetics, with products including Skyrizi, Rinvoq, Qulipta and Botox. Immunology and neuroscience sales are cited as important growth drivers, while the supplied evidence does not give segment-level revenue contributions. Customers include hospitals, pharmacies, clinics and other healthcare providers, with patients and insurers ultimately supporting demand. AbbVie reports FY2025 revenue of $61.2 billion and net income of $4.2 billion, compared with $56.3 billion and $4.3 billion, respectively, in FY2024.
ABBV rose 1.96%, from $285.19 to $290.79. It gained to $286.74 on Monday, slipped modestly over Tuesday and Wednesday to $285.99, then jumped $4.80 on Thursday. The supplied evidence does not date its company developments closely enough to connect them to individual trading sessions: coverage reports a Q3 earnings and revenue beat, stronger immunology and neuroscience sales, and a raised FY2026 adjusted EPS outlook, but does not establish when those items became known relative to the closes. A Zacks market note described a down week amid concerns about AI and oil prices and cited a 2.5% Nasdaq decline; it provides broader context, but does not explain ABBV’s Thursday rise.
AbbVie gained 0.55%, rising from $281.12 on October 12 to $282.68 on October 19. The week was volatile: shares fell to $274.36 on October 13, then rebounded to $283.48 the next day and climbed to a Friday close of $285.42 before retreating on Monday. Reports highlighted late-stage lutikizumab results in hidradenitis suppurativa: the trial met its main goal, with flares in 18.4% of patients versus 28.1% on placebo, while an analyst said efficacy fell short of benchmarks. The supplied evidence does not establish that this news drove the daily moves, and it provides no market context to explain them; the stock’s net gain therefore cannot be attributed confidently to a specific catalyst.
AbbVie rose $15.36, or 5.78%, from $265.76 on Oct. 5 to $281.12 on Oct. 12, advancing at every listed close with no material reversal. The clearest company-specific support in the supplied coverage was positive Phase 3 SKYRIZI data for Crohn’s disease: by week 12, 27.7% of treated patients had little to no gut inflammation, versus 10.2% on placebo. Coverage also described supportive analyst tone, and Morgan Stanley raised its price target to $310 from $296 on Oct. 7. Those items are consistent with the rise, but the evidence does not establish how much they drove trading. Barron’s also cited a broader healthcare rally, though the supplied snippet does not establish its timing relative to AbbVie’s daily gains.
ABBV gained 1.29%, rising from $263.29 to $266.69. The path included a material reversal: shares fell to $259.93 on October 1, then recovered to $262.82 on October 2 and advanced to $265.76 and $266.69 on October 5 and 6. The clearest company-specific positive news in the supplied coverage was AbbVie and Genmab’s Phase 3 EPCORE DLBCL-2 result: epcoritamab plus R-CHOP met its progression-free-survival goal and cut the risk of progression or death by 51% in frontline diffuse large B-cell lymphoma. Coverage also reported FDA designations for AbbVie, but the supplied headline does not specify the designations. No market benchmark or evidence ties the daily moves to broader market conditions.
AbbVie fell 1.96%, from the stated $265.12 starting reference to $259.93 on October 1. The stock rose to $266.28 on Monday, September 28, but then declined at each subsequent close, giving back that gain and finishing below the starting reference. The supplied coverage included company updates on Juvmo’s FDA approval, positive Phase 2 results for zumilokibart, and dermatology data for RINVOQ, but it does not establish that any one of these drove the share-price decline. No market benchmark or broader-market news is supplied to explain the move, so the evidence does not identify a clear trading catalyst.
ABBV rose 0.98%, from $262.51 to $265.08. The supplied closes show a steady climb through Tuesday, when the stock reached $265.21, followed by a small 0.13-point pullback on Wednesday. No company-specific catalyst is clearly tied to the move: the evidence mentions EU approval for Rinvoq in juvenile idiopathic arthritis and a migraine-trial win, but provides no dates that connect either item to this week’s trading. The share-price record covers September 21–23 for the stated week, rather than a full five sessions, and gives no market benchmark or sector data for comparison. On the available evidence, the gain was modest and its drivers remain unidentified.
AbbVie rose 2.07% over the week, from $256.46 to $261.77, extending a recovery that had already carried the stock from $248.78 on September 8 to $257.12 on September 11. The decisive move came on September 14, when shares gained $4.65, or 1.81%, despite Zacks reporting that the broader market declined. No supplied evidence identifies a company-specific announcement, earnings release, guidance change, or analyst action during the week that explains the advance. Instead, trading appears to have reflected continued investor interest in AbbVie’s growth portfolio, including immunology, neuroscience and pipeline developments, alongside valuation support cited by several articles. The stock therefore moved higher against a weaker market, without a clearly documented weekly catalyst.
AbbVie fell $7.64, or 2.98%, from $256.42 to $248.78 over the period. The stock initially advanced, gaining to $259.99 on September 1 and $261.72 on September 2, before reversing over the next two sessions and giving back the entire rise by September 4. It then dropped another 2.99% to $248.78 in the latest session, on volume of 5.57 million shares versus 4.73 million previously. The supplied evidence does not identify a company-specific announcement that explains the reversal. Investor discussion instead centered on valuation, Skyrizi reliance, dividend support and a positive migraine-trial result, while the latest decline was reported as larger than the market's move without a stated AbbVie catalyst.
AbbVie rose $2.06, or 0.80%, over the reported week, moving from $258.15 to $260.21. The stock initially lagged after closing at $256.42 on Monday, then gained 1.4% Tuesday and another 0.7% Wednesday before giving back $1.51, or 0.6%, Thursday. The strongest company-specific support was positive Phase 3 CERVINO data for investigational etentamig in relapsed or refractory multiple myeloma, which strengthened the oncology and pipeline narrative. Coverage also focused on AbbVie’s FY2026 earnings guidance, while the completed $10.9 billion Apogee Therapeutics acquisition reinforced its immunology pipeline. The supplied evidence does not identify a broader market catalyst or quantify the guidance.
AbbVie fell $3.68, or 1.41%, over the week, from $261.83 to $258.15. The stock initially resisted the broader weakness implied by no specific market catalyst in the supplied evidence, closing at $264.52 on Monday and $265.79 on Tuesday. It then reversed, losing $2.89 on Wednesday and another $4.75 on Thursday. The principal company-specific developments were AbbVie’s European regulatory submission for subcutaneous Skyrizi induction in Crohn’s disease, a potentially favorable convenience and access catalyst, and evidence that second-quarter oncology sales fell 2.4% as Imbruvica declined, despite support from Venclexta and newer medicines. The week’s late selling outweighed the earlier Skyrizi-related optimism.
The stock rose 4.39%, from $250.82 to $261.83, with nearly all of the advance concentrated in Tuesday and Wednesday. ABBV gained from $250.33 to $258.92 on Aug. 18, then climbed to $265.97 on Aug. 19 as trading volume increased to 5.54 million shares, before giving back $4.14, or 1.56%, on Aug. 20. The supplied evidence does not identify a material company-specific announcement, earnings release, guidance change, or clinical update during the week. Articles focused mainly on the rally, valuation, financing, insider activity, and institutional holdings. The stock therefore moved without an explicitly documented company catalyst; broader market context is not provided.
AbbVie rose $2.87, or 1.17%, from $245.10 to $247.97 over the week. Trading was volatile rather than steadily directional: the stock fell to $243.80 on Tuesday, rallied to $246.20 Wednesday, retreated to $243.87 Thursday, then recovered on Friday and added a further $1.93 on Monday. The supplied evidence does not identify a company-specific announcement that clearly drove the daily moves. Investor attention around the period focused on AbbVie’s lifted 2026 guidance, strong second-quarter growth, potential neuroscience-drug momentum, and Botox moving closer to a fifth indication, but the timing and market impact of those items are not established. The shares therefore appear to have moved mainly on trading momentum and broader market factors not specified in the evidence.
AbbVie fell $19.40, or 7.37%, from $263.20 to $243.80 over the measured week. Shares were essentially flat through July 29 before declining for four consecutive sessions, including heavier volume on August 3 and 4. The main catalyst was the second-quarter update: AbbVie beat earnings and revenue expectations and raised full-year revenue guidance by $300 million, but cut its 2026 EPS outlook because of the Apogee acquisition, which also increases research and development spending. Strong Skyrizi, Rinvoq, immunology and neuroscience growth therefore failed to offset dilution concerns. Regulatory news was constructive but secondary, with Canadian reimbursement support for Ubrelvy and FDA review of a Botox Cosmetic application.
